Cytek Biosciences (CTKB) vs Rapid Micro Biosystems (RPID)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cytek Biosciences (CTKB) has outperformed Rapid Micro Biosystems (RPID) over the past year, gaining 40.9% versus a loss of 75.7%. Over five years, CTKB leads with a -77.8% price change compared with -94.7% for RPID. Cytek Biosciences is the larger company by market cap ($694.1 million vs $45.0 million), about 15.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTKB | RPID |
|---|---|---|
| Share price | $5.34 | $0.8977 |
| Market cap | $694.11M | $45.03M |
| 1-day change | -0.74% | -4.76% |
| YTD return | +5.74% | -69.04% |
| 1-year return | +40.90% | -75.67% |
| 5-year return | -77.81% | -94.66% |
| Forward P/E | 76.29 | — |
| EPS (TTM) | $-0.62 | $-1.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.21 | $4.94 |
| 52-week low | $3.31 | $0.86 |
| Distance from 52-week high | -14.01% | -81.83% |
| Analyst consensus | none | — |
| Avg. price target upside | +4.12% | — |
| Average volume | 1.03M | 272.65K |
| Shares outstanding | 129.98M | 45.66M |
| Employees | 682 | — |
| Sector | Healthcare | Industrials |
| Industry | Medical Devices | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Cytek Biosciences is about 15.4 times larger than Rapid Micro Biosystems by market value ($694.11M vs $45.03M).
- CTKB has outperformed RPID by 116.6 percentage points over the past year.
- The two companies sit in different sectors: Cytek Biosciences in Healthcare and Rapid Micro Biosystems in Industrials.
About Cytek Biosciences
CTKB stock →Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems.
Healthcare · Medical Devices · 682 employees
CTKB vs RPID FAQ
Which is bigger, Cytek Biosciences or Rapid Micro Biosystems?
Cytek Biosciences (CTKB) is larger, with a market capitalization of $694.11M compared with $45.03M for Rapid Micro Biosystems (RPID).
Which stock has performed better over the past year, CTKB or RPID?
CTKB returned +40.90% over the past 12 months, compared with -75.67% for RPID (price return, excluding dividends). Past performance does not predict future results.
Are Cytek Biosciences and Rapid Micro Biosystems in the same industry?
No. Cytek Biosciences is in the Healthcare sector, while Rapid Micro Biosystems is in Industrials.